Catalyst Event
Amgen Inc (AMGN) · Other
From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)
4/28/2026, 12:00:00 AM
The U.S. FDA's CDER proposed withdrawing the approval for Amgen's Tavneos on April 28, 2026, citing safety concerns and data manipulation. This is expected to have a high market impact (>=10%) due to the loss of a commercial product and regulatory risks, expected.
Korean Translation
2026년 4월 28일, 미국 FDA CDER이 안전성 및 데이터 조작 문제로 암젠 타브네오스의 승인 철회를 제안함. 제품 상실 및 규제 리스크로 인해 10% 이상의 큰 시장 영향이 예상됨, 예상됨.
Related Recent Events
Bristol-Myers Squibb Co (BMY) · Other
The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of August 17, 2026, for its decision on iberdomide for relapsed or refractory multiple myeloma, scheduled. Low impact estimated as the target date is a procedural milestone.
8/17/2026, 12:00:00 AM
Blackstone Inc (BX) · Earnings Release
Blackstone is scheduled to release its Q2 2026 earnings results, with analysts forecasting earnings of approximately $1.34-$1.36 per share, scheduled.
7/23/2026, 12:00:00 AM
Union Pacific Corp (UNP) · Earnings Release
Q2 2026 earnings release is scheduled. Low impact estimated as the date announcement is a routine event; scheduled.
7/23/2026, 12:00:00 AM
Goldman Sachs Group Inc (The) (GS) · Earnings Release
Goldman Sachs' Q2 2026 earnings release is scheduled.
7/14/2026, 12:00:00 AM
NIKE Inc (NKE) · Earnings Release
Q4 Fiscal Year 2026 earnings release is scheduled for June 25, 2026. Low importance as the announcement of the date typically has a minimal market impact.
6/25/2026, 12:00:00 AM
Vistra Corp (VST) · Other
Quarterly dividend of $0.2290 per share with an ex-dividend date of June 22, 2026; low importance estimated as dividends usually cause minor price adjustments, scheduled.
6/22/2026, 12:00:00 AM